Humana Inc: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 3, 2020 and accepted by EDGAR at Nov 3, 2020, 14:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $20.07bn | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $58.09bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2020-07-01 to 2020-09-30 | $2.51bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2020-01-01 to 2020-09-30 | $6.98bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $1.82bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $5.33bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $75.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $211.0m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $450.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $1.49bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $1.34bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $3.64bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $10.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $27.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $10.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $27.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 133,196,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 133,010,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $5.36bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $668.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2020-01-01 to 2020-09-30 | $239.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2020-01-01 to 2020-09-30 | $30.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-09-30 | $7.99bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $27.03bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $38.48bn | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $14.90bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $22.71bn | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $6.06bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-09-30 | $1.72bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2020-09-30 | $15.77bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2020-09-30 | 132,341,451 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-20-000135. Last ingested by Listed: Nov 6, 2026, 14:15 ET. Listed shows no prices and gives no investment advice.